124 related articles for article (PubMed ID: 11122094)
21. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
22. Blast crisis of chronic myeloid leukaemia (CML). I. Presentation simulating acute lymphoid leukaemia (ALL).
Beard MD; Durrant J; Catovsky D; Wiltshaw E; Amess JL; Brearley RL; Kirk B; Wrigley PF; Janossy G; Greaves MF; Galton DA
Br J Haematol; 1976 Oct; 34(2):167-78. PubMed ID: 1067861
[TBL] [Abstract][Full Text] [Related]
23. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen-dependent fibrinolytic activity in normal human lymphocytes: diminished lymphocyte plasminogen activator in chronic lymphocytic leukemia.
Zucker S; Mehling K; Rai K
Am J Hematol; 1985 Aug; 19(4):373-86. PubMed ID: 3927713
[TBL] [Abstract][Full Text] [Related]
25. Screening for mutations of Bcl10 in leukaemia.
Grimwade D; Du MQ; Langabeer S; Rogers J; Solomon E
Br J Haematol; 2000 Jun; 109(3):611-5. PubMed ID: 10886211
[TBL] [Abstract][Full Text] [Related]
26. [Lysine metabolism in acute leukemia].
Hansz J
Acta Haematol Pol; 1979 Oct; 10(4):237-42. PubMed ID: 295172
[TBL] [Abstract][Full Text] [Related]
27. STROMAL CHANGES IN LEUKAEMIC AND RELATED BONE MARROW PROLIFERATIONS.
SANERKIN NG
J Clin Pathol; 1964 Sep; 17(5):541-7. PubMed ID: 14207789
[TBL] [Abstract][Full Text] [Related]
28. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium.
Sprengers ED; Verheijen JH; Van Hinsbergh VW; Emeis JJ
Biochim Biophys Acta; 1984 Sep; 801(2):163-70. PubMed ID: 6541058
[TBL] [Abstract][Full Text] [Related]
29. Target cell in chronic myeloid leukaemia and its relationship to acute lymphoid leukaemia.
Janossy G; Roberts M; Greaves MF
Lancet; 1976 Nov; 2(7994):1058-61. PubMed ID: 62904
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
31. Late relapse after allogeneic bone marrow transplantation for Philadelphia-positive acute lymphoblastic leukaemia.
Mughal T; Morleda J; Goldman J
Acta Haematol; 1993; 89(3):149-51. PubMed ID: 8362603
[TBL] [Abstract][Full Text] [Related]
32. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
Melo JV; Goldman JM
Leukemia; 1992 Aug; 6(8):786-90. PubMed ID: 1353550
[TBL] [Abstract][Full Text] [Related]
33. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
[TBL] [Abstract][Full Text] [Related]
34. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
Kurzrock R; Kantarjian H; Wetzler M; Estrov Z; Estey E; Troutman-Worden K; Gutterman JU; Talpaz M
Exp Hematol; 1993 Jan; 21(1):80-5. PubMed ID: 8417962
[TBL] [Abstract][Full Text] [Related]
35. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
36. Cytochemical demonstration of dihydrofolate reductase in leukaemia and other haematological diseases.
Tzortzatou F
Scand J Haematol; 1977 Jul; 19(1):5-13. PubMed ID: 268023
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens.
Toth B; Wehrmann M; Kaiserling E; Horny HP
J Clin Pathol; 1999 Sep; 52(9):688-92. PubMed ID: 10655992
[TBL] [Abstract][Full Text] [Related]
38. Lipid peroxidation in leukaemia.
Ghalaut VS; Ghalaut PS; Singh S
J Assoc Physicians India; 1999 Apr; 47(4):403-5. PubMed ID: 10778525
[TBL] [Abstract][Full Text] [Related]
39. [Pathological features of neuroleukemia. Changes and lessons].
Garzuly F
Orv Hetil; 1994 Jun; 135(24):1291-5. PubMed ID: 8015823
[TBL] [Abstract][Full Text] [Related]
40. Depressed fibrinolysis in patients with acute leukaemia.
Guarini A; Mussoni L; Gugliotta L; Chetti L; Niewiarowski T; Catani L; Macchi S; Donati MB; Tura S
Br J Haematol; 1987 Jul; 66(3):327-30. PubMed ID: 2441734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
